Dr. Reddy’s Laboratories Ltd ADR (RDY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.91 Billion) by net assets ($375.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RDY equity financing ratio to measure how much of total assets are equity-financed.
Dr. Reddy’s Laboratories Ltd ADR - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Dr. Reddy’s Laboratories Ltd ADR (RDY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jefferies Financial Group Inc
NYSE:JEF
|
-0.097x |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
N/A |
|
Koc Holding AS
IS:KCHOL
|
0.004x |
|
Erie Indemnity Company
NASDAQ:ERIE
|
0.039x |
|
Industrial Bank Of Korea
KO:024110
|
0.054x |
|
Vedanta Limited
NSE:VEDL
|
0.237x |
|
Zebra Technologies Corporation
NASDAQ:ZBRA
|
0.051x |
|
Indus Towers Limited
NSE:INDUSTOWER
|
0.219x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Dr. Reddy’s Laboratories Ltd ADR (RDY) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $337.17 Billion | $46.43 Billion | 0.138x | -14.97% |
| 2024-03-31 | $280.55 Billion | $45.43 Billion | 0.162x | -36.46% |
| 2023-03-31 | $230.99 Billion | $58.87 Billion | 0.255x | +72.76% |
| 2022-03-31 | $190.53 Billion | $28.11 Billion | 0.148x | -99.02% |
| 2021-03-31 | $2.37 Billion | $35.70 Billion | 15.083x | +3.55% |
| 2020-03-31 | $2.05 Billion | $29.84 Billion | 14.566x | +7014.23% |
| 2019-03-31 | $140.20 Billion | $28.70 Billion | 0.205x | +43.61% |
| 2018-03-31 | $126.46 Billion | $18.03 Billion | 0.143x | -17.80% |
| 2017-03-31 | $124.04 Billion | $21.51 Billion | 0.173x | -46.04% |
| 2016-03-31 | $128.34 Billion | $41.25 Billion | 0.321x | +42.90% |
| 2015-03-31 | $111.30 Billion | $25.03 Billion | 0.225x | +4.93% |
| 2014-03-31 | $90.80 Billion | $19.46 Billion | 0.214x | +1076.68% |
| 2013-03-31 | $731.04 Billion | $13.32 Billion | 0.018x | -93.52% |
| 2012-03-31 | $57.44 Billion | $16.15 Billion | 0.281x | +61.44% |
| 2011-03-31 | $45.99 Billion | $8.01 Billion | 0.174x | -43.49% |
| 2010-03-31 | $42.91 Billion | $13.23 Billion | 0.308x | +187.63% |
| 2009-03-31 | $42.05 Billion | $4.50 Billion | 0.107x | -17.63% |
| 2008-03-31 | $47.07 Billion | $6.12 Billion | 0.130x | -54.17% |
| 2007-03-31 | $41.69 Billion | $11.83 Billion | 0.284x | +283.73% |
| 2006-03-31 | $22.27 Billion | $1.65 Billion | 0.074x | -32.37% |
| 2005-03-31 | $20.95 Billion | $2.29 Billion | 0.109x | -42.46% |
| 2004-03-31 | $21.08 Billion | $4.01 Billion | 0.190x | -18.03% |
| 2003-03-31 | $18.78 Billion | $4.35 Billion | 0.232x | -22.97% |
| 2002-03-31 | $15.44 Billion | $4.65 Billion | 0.301x | +156.40% |
| 2001-03-31 | $5.24 Billion | $614.87 Million | 0.117x | -17.97% |
| 2000-03-31 | $99.87 Million | $14.29 Million | 0.143x | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more